Clinical trials: Cemiplimab
Advanced Dedifferentiated Liposarcoma, Locally Advanced Dedifferentiated Liposarcoma
Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma
This phase II trial compares the effect of treatment with palbociclib alone to treatment with palbociclib plus cemiplimab for treating patients with dedifferentiated liposarcoma that may have spread from where it first started to…
- Conditions
- Advanced Dedifferentiated Liposarcoma, Locally Advanced Dedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
- Trial name
- NCT05694871
- Testing
- Palbociclib, Cemiplimab, Magnetic Resonance Imaging
- Where
- 194 sites in United States
- Volunteers
- 77 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Colorectal Cancer
Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer
The purpose of this study is to evaluate the safety and clinical activity of combining cemiplimab, cemiplimab/fianlimab, or cemiplimab/REGN7075 with capecitabine/oxaliplatin (CAPOX) for the neoadjuvant treatment of patients with…
- Trial name
- NCT07281768
- Testing
- Oxaliplatin, Capecitabine, Cemiplimab
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lung Cancer (NSCLC)
Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1
This is a single arm phase II trial enrolling patients with stage II-IIIA non-small cell lung cancer whose disease is deemed amenable for surgical resection and has a PD-L1 level of ≥50%.
- Trial name
- NCT07450183
- Testing
- Cemiplimab, Adjuvant chemotherapy
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Henry Ford Health System
HIV Infections
Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART
The purpose of this study was to evaluate the safety and immunotherapeutic activity of an anti-PD-1 antibody (cemiplimab) in participants with HIV-1 on suppressive combination antiretroviral therapy (cART).
- Trial name
- NCT03787095
- Testing
- Cemiplimab
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cutaneous Squamous Cell Carcinoma
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
The primary objective of the study is to compare disease-free survival (DFS) of patients with high-risk cutaneous squamous cell carcinoma (CSCC) treated with adjuvant cemiplimab, versus those treated with placebo, after surgery…
- Trial name
- NCT03969004
- Testing
- Cemiplimab
- Where
- 166 sites in United States, Australia and 14 more
- Volunteers
- 415 people
- Sponsor
- Regeneron Pharmaceuticals
Clear Cell Renal Cell Carcinoma
Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma
The purpose of this research is to test the safety of PD-1 inhibitor cemiplimab with or without LAG-3 inhibitor fianlimab, and see what effects (good and bad) of cemiplimab either alone or combined with fianlimab has on patients…
- Trial name
- LAG-BOOST (NCT07223541)
- Testing
- Cemiplimab 350 MG Intravenous Solution, Fianlimab 1600 MG Intravenous Solution
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- University of Oklahoma
Carcinoma, Non-Small-Cell Lung
Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
The objective of this trial is to study REGN4659 and cemiplimab in treatment-experienced, non-small cell lung cancer (NSCLC) patients. There are 2 phases of this study: a dose escalation phase and a dose expansion phase.
- Trial name
- NCT03580694
- Testing
- REGN4659, Cemiplimab
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Regeneron Pharmaceuticals
Locally Advanced Head and Neck Squamous Cell Carcinoma
Study of Cemiplimab - TP Induction Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
The purpose of this research study is to determine the safety and tolerability of two dosing schedules of cemiplimab given in combination with cisplatin and docetaxel induction chemotherapy (TPI) in patients with locally advanced…
- Trial name
- NCT05376553
- Testing
- Cemiplimab, Cisplatin, Docetaxel
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Krzysztof Misiukiewicz
Glioblastoma
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with radiation and chemotherapy, in subjects with newly-diagnosed glioblastoma (GBM).
- Trial name
- NCT03491683
- Testing
- INO-5401, INO-9012, Cemiplimab
- Where
- 21 sites in United States
- Volunteers
- 52 people
- Sponsor
- Inovio Pharmaceuticals
Colon and Rectal Cancer
Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)
This study is being conducted to find out if treatment with gemcitabine, cisplatin, nab-paclitaxel, and cemiplimab can shrink previously inoperable tumors enough for surgery.
- Trial name
- GAP Cemi (NCT07433673)
- Testing
- Cemiplimab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Columbia University
Glioblastoma, Recurrent Glioblastoma
ASP8374 + Cemiplimab in Recurrent Glioma
This study is looking at the safety and efficacy of the drug combination of ASP8374 with cemiplimab in people with recurrent malignant glioma.
- Trial name
- NCT04826393
- Testing
- ASP8374, cemiplimab
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- Dana-Farber Cancer Institute
Non-small Cell Lung Cancer, Hepatocellular Carcinoma
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
This study is being done to better understand whether or not cemiplimab by itself and in combination with other treatments given prior to surgery will cause your tumor to respond in a beneficial way; whether the drug(s) are safe…
- Conditions
- Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03916627
- Testing
- cemiplimab, Platinum Doublet, fianlimab
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Regeneron Pharmaceuticals
Bladder Urothelial Carcinoma
A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer
The researchers are doing this study to find out whether stereotactic body radiation therapy (SBRT) in combination with immunotherapy (cemiplimab with or without fianlimab) before cystectomy is an effective and safe treatment for…
- Trial name
- NCT07414992
- Testing
- Stereotactic body radiotherapy, Cemiplimab, Cemiplimab and Fianlimab
- Where
- 7 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Cancer, Fallopian Tube Cancer
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
This study is researching an investigational drug called REGN5668 : alone or, combined with cemiplimab (also known as REGN2810) or, combined with both cemiplimab and fianlimab (also known as REGN3767), or combined with ubamatamab…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer
- Trial name
- NCT04590326
- Testing
- REGN5668, Cemiplimab, Ubamatamab
- Where
- 28 sites in United States, Belgium and 3 more
- Volunteers
- 612 people
- Sponsor
- Regeneron Pharmaceuticals
Breast Cancer
PD-1 +/- IL-4 Inhibition in ER+ Breast Cancer
This proposal is for a Window of Opportunity (WOO) clinical trial using a novel combination of two Health Canada approved agents, cemiplimab (Libtayo) and dupilumab (Dupixent), for off label use in early-stage estrogen receptor…
- Trial name
- NCT05967884
- Testing
- Arm A: Cemiplimab, Arm B: Cemiplimab + Dupilumab
- Where
- 2 sites in Canada
- Volunteers
- 20 people
- Sponsor
- Ottawa Hospital Research Institute
Solid Tumor
A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors
This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.
- Trial name
- NCT06384807
- Testing
- BHV-1510, Cemiplimab
- Where
- 17 sites in United States
- Volunteers
- 500 people
- Sponsor
- Biohaven Therapeutics Ltd.
Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck
Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC
The purpose of this research study is to determine how people with weakened immune systems and unresectable (cannot be removed by surgery) locally recurrent and/or metastatic cutaneous squamous cell carcinoma (CSCC) respond to…
- Trial name
- NCT04242173
- Testing
- Cemiplimab-Rwlc
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Solid Tumor, Adult
First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors
The goal of the clinical trial is to learn about safety, tolerability and preliminary efficacy of IO-108 as monotherapy or in combination with a PD-1 inhibitor in patients with advanced, metastatic solid tumors, and to find a…
- Trial name
- NCT05054348
- Testing
- IO-108, IO-108 + pembrolizumab combination therapy, IO-108 + cemiplimab combination therapy
- Where
- 24 sites in United States
- Volunteers
- 91 people
- Sponsor
- Immune-Onc Therapeutics
HPV-Related Squamous Cell Carcinoma
Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca
To determine if it is feasible to use neoadjuvant immunotherapy (or immunotherapy plus chemotherapy) to reduce treatment intensity and improve long-term quality of life while maintaining very high cure rates.
- Trial name
- MINIMA (NCT04988074)
- Testing
- Cemiplimab
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
The current protocol will examine the use of a plasmid DNA vaccine encoding AR, alone or with T-cell checkpoint blockade, to induce and/or augment therapeutic T-cells following androgen deprivation in patients with newly…
- Trial name
- NCT04989946
- Testing
- Degarelix, pTVG-AR, Nivolumab
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of Wisconsin, Madison